Omlyclo® (omalizumab-igec) - CAM 972HB

Background

FDA-Approved Indications: Omlyclo is an anti-IgE monoclonal antibody and the first FDA-approved interchangeable biosimilar to Xolair® (omalizumab). It is indicated for the following conditions:

  1. Moderate-to-severe persistent asthma in adults and pediatric patients aged 6 years and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids.
  2. Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults aged 18 years and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment.
  3. IgE-mediated food allergy in adults and pediatric patients aged 1 year and older for reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods, in conjunction with allergen avoidance.
  4. Chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years an older who remain symptomatic despite H1-antihistamine treatment.

Policy

Coverage of these drugs is provided when the criteria below is met and for non-preferred products there has been a trial and failure of TWO preferred therapy.

Moderate-to-Severe Allergic Asthma

Initial Authorization Criteria

Omlyclo may be considered medically necessary when all of the following criteria are met:

  1. Diagnosis of moderate-to-severe persistent allergic asthma.
  2. Positive skin test or in vitro reactivity to at least one perennial aeroallergen.
  3. Symptoms remain inadequately controlled despite optimized therapy with:
  • Medium- to high-dose inhaled corticosteroid (ICS)
  • And at least one additional controller (e.g., LABA), when appropriate.
  1. Baseline serum IgE level and body weight are within FDA-approved dosing parameters.
  2. Prescribed by or in consultation with an allergist, immunologist, or pulmonologist.

Reauthorization Criteria

  1. Documentation of positive clinical response, including one or more:
    • Reduction in asthma exacerbations
    • Reduced systemic corticosteroid use
    • Improved Asthma Control Test (ACT) scores
    • Improved lung function (e.g., FEV1)
    • Reduced emergency department visits or hospitalizations
  1. Continued need for maintenance therapy documented by the treating specialist.

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Initial Authorization Criteria

  1. Diagnosis of CRSwNP confirmed by nasal endoscopy or imaging.
  2. Omlyclo will be used as add-on maintenance treatment.
  3. Prescribed by or in consultation with an allergist or otolaryngologist.

Reauthorization Criteria

  1. Positive clinical response demonstrated by one or more:
    • Reduction in nasal polyp size
    • Improved nasal obstruction
    • Improved sense of smell
    • Reduced need for systemic corticosteroids
    • Reduced need for sinus surgery
  1. Continued treatment remains clinically appropriate.

IgE-Mediated Food Allergy

Initial Authorization Criteria

  1. Diagnosis of IgE-mediated food allergy confirmed by clinical history and appropriate testing.
  1. Patient is 1 year of age or older.
  1. Treatment will be used in conjunction with continued food allergen avoidance.
  1. Prescribed by or in consultation with an allergist/immunologist.

Reauthorization Criteria

  1. Documentation of benefit from therapy, including:
    • Reduced allergic reactions from accidental exposure
    • Improved management of food allergy risk
    • Continued specialist recommendation
  1. Patient continues food allergen avoidance measures.

Chronic Spontaneous Urticaria (CSU)

Initial Authorization Criteria

  1. Diagnosis of chronic spontaneous urticaria.
  1. Patient is 12 years of age or older.
  1. Symptoms remain inadequately controlled despite H1-antihistamine therapy.
  1. Prescribed by or in consultation with an allergist, immunologist, or dermatologist.

Reauthorization Criteria

  1. Documentation of positive response demonstrated by:
    • Reduction in hive frequency
    • Reduction in pruritus
    • Improvement in Urticaria Activity Score (UAS7)
    • Improved quality of life
    • Reduced rescue medication use
  1. Continued need for therapy documented by the treating specialist.

References

  1. OMLYCLO® (omalizumab-igec) Prescribing Information. Celltrion USA, 2025.
  2. U.S. Food and Drug Administration. OMLYCLO (omalizuma-igec) Highlights of Prescribing Information.
  3. OMLYCLO® (omalizumab-igec) FDA-Approved Interchangeable Biosimilar. elltrion USA. turn15search13
  4. Global Initiative for Asthma (GINA). Global Strategy or Asthma Management and Prevention. Current version.
  5. AAAAI/ACAAI Joint Task Force. Practice Parameters for Asthma, Food Allergy, and Chronic Urticaria. Current versions.

Coding Section

Code

Number

Description

HCPCS

J2357

Injection, omalizumab, 5 mg

 

Q5154

Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg

ICD-10

J33.0

Polyp of nasal cavity

 

J45.40

Moderate persistent asthma, uncomplicated

 

J45.41

Moderate persistent asthma with (acute) exacerbation

 

J45.42

Moderate persistent asthma with status asthmaticus

 

J45.50

Severe persistent asthma, uncomplicated

 

J45.51

Severe persistent asthma with (acute) exacerbation

 

J45.52

Severe persistent asthma with status asthmaticus

 

L50.1

Idiopathic urticaria

 

L50.6

Contact urticaria

 

L50.8

Other urticaria

 

L50.9

Urticaria, unspecified

 

T78.40XA

Allergy, unspecified, initial encounter

 

T78.40XD

Allergy, unspecified, subsequent encounter

 

T78.40XS

Allergy, unspecified, sequela

 

Z91.010

Allergy to peanuts

 

Z91.013

Allergy to seafood

 

Z91.040

Latex allergy status

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2026 Forward

10/01/2026

New Policy

Complementary Content
${loading}